Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.

Medicinal chemistry (Shariqah (United Arab Emirates)) - 1 Jan 2018

Wu Fangrui, Cheng Gang, Yao Yuan, Kogiso Mari, Jiang Hong, Li Xiao-Nan, Song Yongcheng

Abstract excerpt

BACKGROUND: R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer. More chemotypes of inhibitors of IDH1(R132H) are therefore needed. OBJECTIVE: The study aimed to develop a new class of IDH1(R132H) inhibitors as potent antitumor agents. METHOD: A biochemical assay was developed to find inhibitors of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Enzyme Inhibitors

Share to Gene Expression Regulation, Enzymologic

Share to Isocitrate Dehydrogenase

Share to Molecular Structure

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 29792149
DOI: 10.2174/1573406414666180524093659
PMCID: PMC6205205

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.PMID 29792149Read ↗

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.Semantic proximity Read ↗

Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.Semantic proximity Read ↗

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read ↗

Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.Semantic proximity Read ↗

Isocitrate dehydrogenase gene variants in cancer and their clinical significance.Semantic proximity Read ↗

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.Semantic proximity Read ↗

Overexpression of isocitrate dehydrogenase-1R¹³²H enhances the proliferation of A172 glioma cells via aerobic glycolysis.Semantic proximity Read ↗

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.Semantic proximity Read ↗

Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).Semantic proximity Read ↗

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.Semantic proximity Read ↗

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read ↗

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.